SCHEMBL488865

SCHEMBL488865

Nc1nccc(-c2ccc3[nH]cc(CN4CCCCC4)c3c2)c1OCc1c(Cl)cccc1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.41
HTT P42858 2/20 0.41
KDM4E B2RXH2 2/20 0.41
MAPK1 P28482 1/20 0.41
S1PR1 P21453 1/20 0.41
JAK2 O60674 1/20 0.41
RAB9A P51151 1/20 0.41
DRD2 P14416 4/20 0.38
DRD4 P21917 4/20 0.38
DRD3 P35462 4/20 0.38
METAP2 P50579 1/20 0.38
NPC1 O15118 1/20 0.38
HTR1D P28221 2/20 0.38
HTR1B P28222 2/20 0.38
KCNH2 Q12809 1/20 0.37
SCN9A Q15858 1/20 0.37
HRH3 Q9Y5N1 1/20 0.35
POLB P06746 1/20 0.35
TSHR P16473 1/20 0.35
BDKRB1 P46663 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL488881 0.99 S1PR1 (0.41) LMNAHTTKDM4EMAPK1S1PR1
SCHEMBL487309 0.82 MET (0.52) LMNAHTTKDM4EMAPK1S1PR1
SCHEMBL488855 0.81 MPO (0.41) LMNAKDM4EMAPK1JAK2HTR1D
SCHEMBL488007 0.81 MET (0.53) LMNAHTTKDM4EMAPK1S1PR1
SCHEMBL488422 0.74 MET (0.61) LMNAKDM4ES1PR1JAK2DRD2
SCHEMBL488866 0.73 GABRP (0.43) LMNAHTTKDM4EMAPK1S1PR1
SCHEMBL488882 0.72 GABRP (0.44) LMNAHTTKDM4EMAPK1S1PR1
SCHEMBL488123 0.71 MET (0.49) LMNAHTTKDM4ES1PR1DRD2
SCHEMBL30453435 0.71 MET (0.49) LMNAHTTKDM4ES1PR1DRD2
SCHEMBL14631921 0.70 MET (0.47) LMNAHTTS1PR1DRD2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106197-B2 Aminoheteroaryl compounds as protein kinase inhibitors PFIZER INC. (US) 2012-01-31 US disclosed
US-20070072874-A1 Aminoheteroaryl compounds as protein kinase inhibitors SUGEN, INC. 2007-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072874-A1 Aminoheteroaryl compounds as protein kinase inhibitors MET, MAP4K1, MAP4K2 LMNA 4389/4885HTT 4481/4885KDM4E 875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.